BioNxt Solutions Inc.
4.3.2024 09:08:21 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic ("PK") study for its oral dissolvable film ("ODF") based proprietary Cladribine product for the treatment of Multiple Sclerosis ("MS") has been completed. Results will be reported by the Company when available. The PK study closely follows the unanimously successful results of the ODF Cladribine toxicity study, announced February 7, 2024.
BioNxt is developing a proprietary hybrid-generic ODF Cladribine dosage form, directed at the MS market. Cladribine tablets are approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The comparative PK study was carried out by a European contract research organization in accordance with EU medical regulatory guidelines using animal models and a single administration of either sublingual (ODF) or oral (tablet) Cladribine. Blood testing and analysis was carried out pre-dose and at up to six time points after administration using blood aliquots.
BioNxt has accelerated its Cladribine ODF program in a priority manner with GMP product development and batch production planned for Q1 and Q2 2024 with the European Investigational Medicinal Product Dossier (IMPD) preparation and submission planned for Q2 2024.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
BioNxt's wholly owned subsidiary is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of innovative, non-invasive drug delivery systems, particularly transdermal patches and sublingual strips for the delivery of active pharmaceutical ingredients for the treatment of pain and neurological conditions. According to Precedence Research, the global pharmaceutical drug delivery market size was valued at USD 1,525 billion in 2022 and expected to surpass approximately USD 2,047 billion by 2030.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Hugh Rogers, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds23.6.2026 06:45:00 CEST | Press release
"What CTOs Think 2026: Scaling the agentic enterprise with confidence" reveals for the first time, innovation, not efficiency, as the primary driver of digital investment, signaling a move from cost-focused optimization toward growth. ZURICH, SWITZERLAND / ACCESS Newswire / June 23, 2026 / New research released today by Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, shows that CTO confidence in scaling AI is declining, falling to 48% in 2026 from 82% in 2024 - even as AI adoption accelerates and enterprises face growing pressure to turn ambition into execution at scale. Image: What CTOs Think 2026: Scaling the agentic enterprise with confidence. Source: Akkodis The third edition of Akkodis' What CTOs Think report, What CTOs Think 2026: Scaling the agentic enterprise with confidence, features insights from 500 Chief Technology Officers (CTOs) as part of the Adecco Group's Business Leaders 2026 research of 2,000 C-suite executives, The human prem
LiberNovo Prime Sale Fully Launches June 23: Full Chair Lineup and Accessories, Up to 49% Off23.6.2026 04:00:00 CEST | Press release
The limited Omni Premium Bundle headlines a flash sale across the EU and UK, stacked with tiered gifts, a prize wheel, and triple loyalty points, from June 23 through July 11. HONG KONG, HK / ACCESS Newswire / June 22, 2026 / LiberNovo today opened one of its biggest sales of the year. From June 23 through July 11, the entire collection goes on sale across the EU and UK with savings of up to 49% off, and the headline deal is the Omni Premium Bundle: a limited flash-sale price on the original Omni, starting from €939 ( £869) up to 49% off, the chair that started it all, available only while clearance stock lasts. Accessories and the rest of the range join at Prime Sale pricing too, making it the best time of the year to build your complete setup. Every LiberNovo chair is built on the world's first dynamic ergonomic design. A flexible backrest bends and moves with you as you shift, lean, and change position, so your support follows your body instead of holding you in one pose. A powered
Leggett Dynamics Launches Mid-Class Massage System & Makes Luxury Comfort Accessible on High-Volume Programs22.6.2026 13:00:00 CEST | Press release
DETROIT, MI / ACCESS Newswire / June 22, 2026 / Leggett Dynamics today launched its Mid-Class Massage System (MCM), a breakthrough non-electronic innovation that makes premium massage more accessible beyond the luxury vehicle segment. Now in production with a global OEM, MCM was also shortlisted for the 2026 Auto Tech Partnership Award for industry-leading innovation and collaboration. Breakthrough by Design MCM creates a distinctive massage experience with a compact 30 x 35 mm module that uses the Coandă effect, an air jet's natural tendency to follow a curved surface. With no electronics or moving parts, it reduces complexity and cost, making a premium experience accessible to more vehicle segments and consumers. Balancing Innovation, Speed and Cost "Automakers must balance innovation, speed and cost while consumers expect more personalized, affordable, premium experiences," said Julien Rea, VP of Global Innovation & Engineering at Leggett Dynamics. "Leggett Dynamics' Mid-Class Massa
EcoModular Advances EIC STEP Scale Up Application to Support European Manufacturing Expansion22.6.2026 09:55:00 CEST | Press release
AI-native robotics platform engages European innovation-funding specialist Catalyze to prepare its submission to the European Innovation Council's STEP Scale-Up programme, with its EU Manufacturing Hub as the anchor of a planned European scale-up DUBLIN, IE / ACCESS Newswire / June 22, 2026 / EcoModular, the AI-native robotics platform for volumetric manufacturing operated by Ascotway Limited and advancing a Nasdaq Capital Market direct listing, today announced that it has engaged Catalyze B.V., a leading European innovation-funding consultancy, to prepare and submit an application to the European Innovation Council (EIC) STEP Scale-Up programme. The application is being prepared for the programme's evaluation batch dated 9 September 2026. The EIC STEP Scale-Up programme forms part of the European Union's Strategic Technologies for Europe Platform (STEP) and is administered by the European Innovation Council. It is designed to provide investment support to European companies scaling st
Bear Robotics to Acquire Kinisi Robotics, Completing Its End-to-End Physical AI Robotics Platform22.6.2026 09:00:00 CEST | Press release
Kinisi adds the manipulation AI layer that completes Bear's multi-robot Physical AI platform - extending Bear's deployed fleet from moving and delivering to handling physical work itself. REDWOOD CITY, CA / ACCESS Newswire / June 22, 2026 / Bear Robotics today announced it has signed a definitive agreement to acquire Kinisi Robotics, in a transaction that will make Kinisi part of Bear. On closing, Kinisi's KR1 humanoid robot, its Bristol-based engineering team, and its Physical AI capabilities will be integrated into Bear Robotics, completing Bear's end-to-end Physical AI robotics platform. The transaction is expected to close in the coming days. Bear has built the world's most widely deployed fleet of service robots - more than 16,000 shipped into commercial service worldwide. Bear's robots already work together as one coordinated team through agentic multi-robot orchestration, moving freely through busy, changing spaces instead of following fixed tracks or routes. Most robotics compa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom